Exiqon CEO: Extremely disappointing adjustment
Lars Kongsbak, CEO in Exiqon, is deeply disappointed with last week’s lowering of the company's full year guidance, which is caused by a unexpected turn of events. But he is hopeful about the long term business prospects.
BY BENJAMIN WERNER CHRISTENSEN
A surprise shift in customer preferences from older products to brand new ones is the direct reason that the Danish gene analysis company Exiqon lowered its full year revenue guidance from DKK 150 million to DKK 135 million last week.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
“I think they have done a great job”
For abonnenter
Exiqon CEO: Not completely satisfied
For abonnenter
Exiqon CEO: Difficult to find Danish workers
For abonnenter
